Storied pharmaceutical company<\/a> Bristol Myers Squibb has a long history of paying dividends; it has done so for 94 consecutive years. It’s also declared dividend raises for 17 years in a row, most lately with its mid-December declaration of an upcoming $0.63-per-share quarterly payout. That’s a 1.6% increase.<\/p>\n Bristol Myers Squibb focuses on developing and selling drugs in the therapeutic areas of cardiovascular disease, immune disorders, and oncology. It divides its commercialized drug portfolio into “growth” medications with at least several years of patent exclusivity remaining, and “legacy” products that are either approaching the patent cliff or have already lost exclusivity.<\/p>\n The company has blockbuster drugs in both categories; the growth portfolio is anchored by cancer treatment Opdivo, and legacy’s top seller these days is the blood-thinner medication Eliquis (codeveloped and marketed with fellow pharmaceutical major Pfizer).<\/p>\n True to its name, the growth portfolio has been the motor for top-line improvement lately. In the third quarter, sales of drugs in that category increased by 18% year over year to $6.9 billion. This was fortunate because it offset the 12% drop in legacy revenue, and helped boost overall revenue by 3% to $12.2 billion.<\/p>\n BMS has been profitable lately and at comfortable margins. Even though non-GAAP (adjusted) net income fell during the period by nearly 11%, it still landed well in the black, at $3.3 billion.<\/p>\n For pharmaceutical companies, a large and robust portfolio typically means strong free cash flow (FCF), and Bristol Myers Squibb generates considerable amounts of it. Annual FCF tends to land in the low-11-figure range; in the third quarter, this was over $5.9 billion, far more than enough to fund the nearly $1.3 billion paid out in dividends.<\/p>\n To me, Bristol Myers Squibb is an excellent choice for a reliable pharmaceutical company that pays a compelling dividend. Yield approaches 5% these days, putting it well above that of most healthcare companies and of many dividend-paying companies, period.<\/p>\n The company’s next distribution will be paid on Feb. 2, 2026, to investors of record as of Jan. 2. At the most recent closing share price, it would yield 4.8%.<\/p>\n Zoetis is a different animal (pun intended) than Bristol Myers Squibb. Yes, it’s also a pharmaceutical company, but one that’s entirely focused on animal health. It’s the largest such pure-play animal health drugmaker worldwide, with an estimated market share of around 20%.<\/p>\n The company is also a steady and reliable dividend payer, having distributed a dividend in every quarter since being spun out of busy Pfizer in 2013. Earlier this month, it pulled the lever on its latest dividend raise, hiking the quarterly distribution by 6% to $0.53 per share.<\/p>\n One great advantage of being a drug developer focused on animals rather than humans is that the business is smaller and more insular. Only a few specialty medicine makers exist at the top of this food chain, and happily, Zoetis is the leader of the pack.<\/p>\n This makes for a very healthy and growing business, especially since pet ownership in the U.S. has increased significantly — 66% of American households owned a pet, per a 2023-2024 survey from the American Pet Products Association, up notably from 56% in 1988. Roughly two-thirds of Zoetis’ sales come from medications for pets (the remainder comes from products for livestock animals).<\/p>\n Over the past five years, annual revenue has increased steadily, advancing from $6.7 billion in 2020 to just under $9.3 billion only four years later. Net income also improved sequentially over that stretch, from over $1.6 billion in the former year to almost $2.5 billion in 2024.<\/p>\n Zoetis should continue to post top- and bottom-line growth on the back of that trend in pet ownership. A rising global population will also boost demand for animal protein, which in turn will support a rise in the company’s livestock business. Meanwhile, its pipeline is extensive and diverse, and it devotes considerable resources to developing new medications.<\/p>\n In my view, Zoetis is a standout niche company in the pharmaceutical sector, and with those strong fundamentals, it’s certainly worthy of inclusion in any stock portfolio.<\/p>\n Zoetis’ upcoming payout will be dispensed on March 3, 2026, to stockholders of record as of Jan. 20. It yields an estimated 1.8%.<\/p>\n Before you buy stock in Bristol Myers Squibb, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Bristol Myers Squibb wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $509,955!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,089,460!*<\/p>\n Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 968% \u2014 a market-crushing outperformance compared to 193% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n See the 10 stocks \u00bb<\/a><\/p>\n *Stock Advisor returns as of December 15, 2025<\/p>\n Eric Volkman<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb, Pfizer, and Zoetis. The Motley Fool has a disclosure policy<\/a>.<\/p>\n Image source: Getty Images. <\/p>\n
Image source: Getty Images. <\/p>\n